

10. (Amended) A composition according to claim 1, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.


REMARKS

Entry of this preliminary amendment is requested at the U.S. Patent and Trademark Office's earliest convenience.

Respectfully submitted,

FAY, SHARPE, FAGAN,
MINNICH & McKEE, LLP

By:



Richard M. Klein
Reg. No. 33,000
1100 Superior Avenue
Seventh Floor
Cleveland, Ohio 44114
Telephone: 216-861-5582
Facsimile: 216-241-1666
E-mail: rklein@faysharpe.com

Attachment - Version With Markings to Show Changes Made

lab429a.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Please amend claims **8, 9 and 10** (i.e. additions are underlined and deletions are bracketed) to read as follows:

IN THE CLAIMS:

8. (Amended) A composition according to [any of claims 1 and 4 to 7] claim 1, wherein the C-terminus of the adrenomedullin is amidated.

9. (Amended) A composition according to [any of claims 1 and 4 to 7] claim 1, wherein Gly is added to the C-terminus of the adrenomedullin.

10. (Amended) A composition according to [any of claims 1 and 4 to 7] claim 1, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.